PROCEPT BioRobotics Corporation Common Stock (PRCT)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style exercise: what am I paying for, and what evidence supports it? PROCEPT sells robotic systems for benign prostatic hyperplasia, with revenue growing from $136.2M in FY2023 to $224.5M in FY2024 and $308.1M in FY2025. That is real top-line progress. But the company has not earned a profit: FY2025 net loss was $95.6M, or diluted EPS -$1.72, and in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $94.5M with net loss $26.9M, or -$0.47 per diluted share. Trailing free cash flow is -$84.9M, a FairStock FCF yield of -7.8%. So growth is funded by cash burn, not owner earnings. At $19.10 close on 2026-10-13, market cap is $1.1B. The P/E is not meaningful at -9.79, while FairStock P/B is 3.22. For a money-losing device maker, that is not a Graham bargain; I want assets or earnings, and I see a negative 30.24% ROE and -14.75% ROCE. The balance sheet is not heavily levered at D/E 0.23, and Altman Z 3.57 is not distress-like, but Piotroski 4/9 is mediocre. The Lynch screen finds no category because losses persist in each of the last four years. A moat may develop if AquaBeam/HYDROS becomes standard care, but the numbers do not yet prove pricing power or profitability. Revenue growth near 19% is encouraging; profit growth of -37.20% is not. I would wait for consistent positive net income and free cash flow before calling it cheap.

In plain English: PROCEPT makes robotic systems for treating an enlarged prostate. The business is growing sales but still loses money and burns cash, and it has not yet shown a profit. At $19.10 per share, the price looks expensive compared with current losses unless future profits grow a lot.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer